Predictive modeling of COPD exacerbation rates using baseline risk factors

Autor: Dave Singh, John R. Hurst, Fernando J. Martinez, Klaus F. Rabe, Mona Bafadhel, Martin Jenkins, Domingo Salazar, Paul Dorinsky, Patrick Darken

Publikováno v: Therapeutic Advances in Respiratory Disease, Vol 16 (2022)

Background: Demographic and disease characteristics have been associated with the risk of chronic obstructive pulmonary disease (COPD) exacerbations. Using previously collected multinational clinical trial data, we developed models that use baseline

Externí odkaz: https://doaj.org/article/0c8b5615f753494089b2fdb3a678df75

Letter to the Editor Regarding 'Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-Analysis'

Autor: Jonathan Marshall, Akanksha Sharma, Patrick Darken, Mario Ouwens, Barinder Singh, Deniz Tansey-Dwyer

Publikováno v: Advances in Therapy. 40:2549-2555

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::432360659af5b97e900637f9ea90180f
https://doi.org/10.1007/s12325-023-02491-4

Benefits of Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate on COPD Exacerbations, Lung Function, Symptoms, and Quality of Life Across Blood Eosinophil Ranges: A Post-Hoc Analysis of Data from ETHOS

Autor: Mona Bafadhel, Klaus F Rabe, Fernando J Martinez, Dave Singh, Patrick Darken, Martin Jenkins, Magnus Aurivillius, Mehul Patel, Paul Dorinsky

Publikováno v: Bafadhel, M, Rabe, K F, Martinez, F J, Singh, D, Darken, P, Jenkins, M, Aurivillius, M, Patel, M & Dorinsky, P 2022, ' Benefits of Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate on COPD Exacerbations, Lung Function, Symptoms, and Quality of Life Across Blood Eosinophil Ranges : A Post-Hoc Analysis of Data from ETHOS ', International journal of chronic obstructive pulmonary disease, vol. 17, pp. 3061-3073 . https://doi.org/10.2147/COPD.S374670

Mona Bafadhel,1 Klaus F Rabe,2 Fernando J Martinez,3 Dave Singh,4 Patrick Darken,5 Martin Jenkins,6 Magnus Aurivillius,7 Mehul Patel,6 Paul Dorinsky8 1Department of Immunobiology, School of Immunology and Microbial Sciences, Faculty of Life Sciences

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::08dc180daecfc1a022a94f7792085965
https://doi.org/10.2147/copd.s374670

Treatment Trials in Young Patients with Chronic Obstructive Pulmonary Disease and Pre-Chronic Obstructive Pulmonary Disease Patients: Time to Move Forward

Autor: Ruth Tal-Singer, Carla A. Da Silva, Gavin C. Donaldson, Fernando D. Martinez, Paul Dorinsky, Robert A. Wise, Hana Müllerová, MeiLan K. Han, Dave Singh, N Locantore, David M.G. Halpin, Jerry A. Krishnan, Peter M.A. Calverley, Sanjay H. Chotirmall, Jørgen Vestbo, Klaus F. Rabe, Mark T. Dransfield, David Price, Surya P. Bhatt, Paul Jones, Fernando J. Martinez, Rosa Faner, Claus Vogelmeier, Bartolome R. Celli, Patrick Darken, Colin Reisner, Jadwiga A. Wedzicha, Bradul Chowdhury, James P. Allinson, Alvar Agusti

Publikováno v: Am J Respir Crit Care Med
Martinez, F D, Agusti, A, Celli, B R, Han, M K, Allinson, J, Bhatt, S P, Calverley, P, Chotirmall, S H, Chowdhury, B, Darken, P, Da Silva, C A, Donaldson, G, Dorinsky, P, Dransfield, M, Faner, R, Halpin, D M, Jones, P, Krishnan, J A, Locantore, N, Martinez, F D, Mullerova, H, Price, D, Rabe, K F, Reisner, C, Singh, D, Vestbo, J, Vogelmeier, C F, Wise, R A & Tal-singer, R 2022, ' Treatment Trials in Young Patients with Chronic Obstructive Pulmonary Disease and Pre–Chronic Obstructive Pulmonary Disease Patients : Time to Move Forward ', American Journal of Respiratory and Critical Care Medicine, vol. 205, no. 3, pp. 275-287 . https://doi.org/10.1164/rccm.202107-1663SO

Chronic obstructive pulmonary disease (COPD) is the end result of a series of dynamic and cumulative gene–environment interactions over a lifetime. The evolving understanding of COPD biology provides novel opportunities for prevention, early diagno

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6164e9059116766e314913dedd0a9ee0
https://pubmed.ncbi.nlm.nih.gov/34672872

Reduced All-Cause Mortality in the ETHOS Trial of Budesonide/Glycopyrrolate/Formoterol for Chronic Obstructive Pulmonary Disease. A Randomized, Double-Blind, Multicenter, Parallel-Group Study

Autor: Gary T. Ferguson, Kimberly Rossman, Dave Singh, Roopa Trivedi, Earl St Rose, Shaila Ballal, Paul Dorinsky, Fernando J. Martinez, Magnus Aurivillius, Patrick Darken, Colin Reisner, Klaus F. Rabe, Jadwiga A. Wedzicha, Chen Wang

Publikováno v: American Journal of Respiratory and Critical Care Medicine

Rationale: In the phase III, 52-week ETHOS (Efficacy and Safety of Triple Therapy in Obstructive Lung Disease) trial in chronic obstructive pulmonary disease (COPD) (NCT02465567), triple therapy with budesonide/glycopyrrolate/formoterol fumarate (BGF

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1a1058cbdb73d18dbf60fe345e32e86a
http://europepmc.org/articles/PMC7924571